Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Chinese Medical Journal|December 15, 2011
XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancerXiao-Li Zhu, Xin-Chen Sun, Bao-An Chen, et al.
Chinese Medical Journal|May 6, 2011
Silencing of high mobility group A1 enhances gemcitabine chemosensitivity of lung adenocarcinoma cellsYuan-Dong Cao, Pei-Lin Huang, Xin-Chen Sun, et al.
Cancer Science|September 5, 2020
Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survivalShu-Kui Qin, Qing Li, Jian Ming Xu, et al.
The Oncologist|April 21, 2022
A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal CarcinomaYang Zhang, Fan Luo, Yu-Xiang Ma, et al.
Future Oncology (London, England)|November 10, 2020
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, et al.
Chinese Journal of Cancer|October 1, 2011
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trialZhong-Zhen Guan, Jian-Ming Xu, Rong-Cheng Luo, et al.
Chinese Medical Journal|April 12, 2012
Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA studyBing-he Xu, Ze-fei Jiang, Zhen-zhou Shen, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|August 30, 2013
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]Lin Shen, Jian-ming Xu, Feng-yi Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III studyTaroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, et al.
Journal of Cancer Research and Clinical Oncology|April 17, 2021
A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX)Yuan Cheng, Shu-Kui Qin, Jin Li, et al.
Pageof 6